PATENT CLAIM ANALYSIS

Application Number: 16415561
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-09
Patent Classification: ["514", "178000"]

Abstract:
The present invention relates to pharmaceutical compositions and kits comprising pharmaceutical compositions, and methods for administering pharmaceutical compositions comprising active contraceptive drugs in a patient. Specifically, the pharmaceutical compositions may comprise progestogen-only contraceptives (“POC”), such as Drospirenone.

Claim (Index 169):
A method of providing contraception in a patient, the method comprising:\n administering orally daily under a 28 consecutive day dosing regimen an active pharmaceutical composition comprising about 2 mg to about 6 mg of drospirenone and one or more pharmaceutically-acceptable excipients to said patient; wherein said 28 consecutive day dosing regimen comprises:\n administering said active pharmaceutical composition for 24 consecutive days followed by 4 consecutive days wherein no active pharmaceutical composition is administered to said patient; and \n administering said active pharmaceutical composition daily at approximately the same time of day such that the interval between two dosages is approximately 24 hours; \n wherein said pharmaceutical composition, when orally administered to said patient under fasting conditions, provides a pharmacokinetic profile for drospirenone having:\n (i) a mean T max  ranging from about 2.2 hours to about 6 hours; \n (ii) a mean C max  which is less than about 30 ng/ml; and \n (iii) an AUC oh-tlast  which is at least 300 ng\u00b7h/ml; \n wherein the dissolution rate of said particle form of said drospirenone in said pharmaceutical composition is such that when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method: no more than 50% of said drospirenone initially present in said pharmaceutical composition is dissolved within 30 minutes, and at least 50% of said drospirenone is dissolved in a time range from 3 hours to 4 hours; and wherein said pharmaceutical composition does not contain an estrogen.

Metadata:
- Claim Count in Document: 87.0
- Percentile: 100.0
- Lexical Diversity: 1.31429
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16415599', '14748147', '15433427', '16223522', '16223556']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7881568585860005
- 35 USC 102 Novelty (BERT): 0.6892828484984854
- Combined Prediction Score: 0.7782694575772491
- Mean Citation Score: 552.042656
- Max Citation Score: 792.7397
- Similarity Product: 682.8177408431827

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test